Treatment
Somatostatin clinical trials
We’re tracking 31 recruiting studies that include Somatostatin, each written for real people, not researchers, below.
Recruiting studies
- NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT06690957Recruiting
SSTR PET scan for people with certain tumors
This study uses a special type of PET scan (called SSTR PET/CT) to look at tumors that may have a specific receptor. The scan helps doctors see where these tumors are and how active they are.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT06784752RecruitingPhase 3
Testing a targeted radiation therapy for advanced neuroendocrine tumors
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Scottsdale, ArizonaAges 12–100 - NCT06930625RecruitingPhase 3
Study of Debio 4126 for acromegaly patients on current therapy
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
Los Angeles, CaliforniaAges 18 years+ - NCT07064746Recruiting
Special imaging scans for children with neuroblastoma
This study tests two special types of imaging scans that look for neuroblastoma tumors. The imaging uses safe radioactive tracers to help doctors better see the cancer and plan treatment.
Nanjing, JiangsuAges Up to 18 years - NCT07165132RecruitingPhase 1
RYZ401 for advanced neuroendocrine tumors
This trial tests an experimental drug called RYZ401 for people with advanced neuroendocrine tumors (NETs) that show a certain marker on scans. The drug is designed to target the tumor cells directly and may be a new option for those who have not had a similar type of targeted radiation therapy.
Iowa City, IowaAges 18 years+ - NCT07195500Recruiting
Imaging scans for neuroblastoma and related tumors
This trial uses special PET/CT or SPECT/CT scans that light up certain types of tumor cells (neuroblastoma and pheochromocytoma/paraganglioma). The scans help doctors see where the cancer is, how far it has spread, and whether treatment is working.
Nanjing, JiangsuAges 6 months+
Common questions
- Are there clinical trials studying Somatostatin?
- Yes. Clin2 currently lists 31 recruiting studies that include Somatostatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Somatostatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Somatostatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Somatostatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.